Success Metrics

Clinical Success Rate
100.0%

Based on 10 completed trials

Completion Rate
100%(10/10)
Active Trials
10(48%)
Results Posted
100%(10 trials)

Phase Distribution

Ph phase_3
4
19%
Ph not_applicable
1
5%
Ph phase_4
2
10%
Ph phase_2
11
52%

Phase Distribution

0

Early Stage

11

Mid Stage

6

Late Stage

Phase Distribution18 total trials
Phase 2Efficacy & side effects
11(61.1%)
Phase 3Large-scale testing
4(22.2%)
Phase 4Post-market surveillance
2(11.1%)
N/ANon-phased studies
1(5.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

10 of 10 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

10

trials recruiting

Total Trials

21

all time

Status Distribution
Active(10)
Completed(10)
Other(1)

Detailed Status

Completed10
Active, not recruiting5
Recruiting5
unknown1

Development Timeline

Analytics

Development Status

Total Trials
21
Active
10
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 211 (61.1%)
Phase 34 (22.2%)
Phase 42 (11.1%)
N/A1 (5.6%)

Trials by Status

unknown15%
active_not_recruiting524%
recruiting524%
completed1048%

Recent Activity

Clinical Trials (21)

Showing 20 of 21 trialsScroll for more
NCT02262806Phase 2

Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy

Active Not Recruiting
NCT02262832Phase 3

Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy

Active Not Recruiting
NCT06679270Phase 3

Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy

Recruiting
NCT02404896

Expanded Access Metreleptin Study

Unknown
NCT06502990Phase 3

Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy

Recruiting
NCT02325674

MEASuRE: Metreleptin Effectiveness And Safety Registry

Recruiting
NCT06305182Phase 2

Metreleptin in Anorexia Nervosa

Recruiting
NCT04026178Phase 4

Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy

Completed
NCT05164341Phase 3

Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL

Active Not Recruiting
NCT06484868Phase 4

Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy

Recruiting
NCT05351164Phase 2

Evaluation of Safety and Efficiency of Metreleptin Treatment for Patients With Multiple Symmetric Lipomatosis (MSL)

Active Not Recruiting
NCT00085982Phase 2

Effect of Metreleptin Therapy in the Treatment of Severe Insulin Resistance

Active Not Recruiting
NCT04063488

The Effects of Metreleptin in Congenital Leptin Deficiency

Completed
NCT02654977Phase 2

CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy

Completed
NCT01778556Phase 2

Short-term Effects of Leptin in People With Lipodystrophy

Completed
NCT00596934Phase 2

Recombinant Leptin Therapy for Treatment of Nonalcoholic Steatohepatitis (NASH)

Completed
NCT01679197Phase 2

Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy

Completed
NCT00025883Phase 2

Leptin to Treat Lipodystrophy

Completed
NCT00677313Not Applicable

An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy

Completed
NCT00673387Phase 2

Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects

Completed

Drug Details

Intervention Type
DRUG
Total Trials
21